Meeting News

Toxicity minimal with novel transplantation approach for transfusion-dependent thalassemia

March 11, 2020
ORLANDO — Nonmyeloablative conditioning in combination with post-transplant cyclophosphamide and thiotepa appeared feasible for patients with…
Meeting News

Older allogeneic HSCT recipients receive as many potentially inappropriate medications as younger counterparts

March 6, 2020
ORLANDO — Individuals aged 65 years or older received potentially inappropriate medications after allogeneic hematopoietic stem cell…
Meeting NewsPerspective

Targeted conditioning improves transplant rate for relapsed, refractory AML

February 28, 2020
ORLANDO — Targeted conditioning with anti-CD45 iodine apamistamab enabled older, heavily pretreated patients with relapsed or refractory acute…
Meeting NewsPerspective

Individualized anti-thymocyte globulin dosing improves immune reconstitution after HSCT

February 28, 2020
ORLANDO — Individualized dosing of rabbit anti-thymocyte globulin significantly improved CD4-positive T-cell recovery after allogeneic…
Meeting News

Noninvasive candidiasis, viral infections common after CAR T-cell therapy

February 26, 2020
ORLANDO — Infectious complications such as noninvasive candidiasis and opportunistic viral infections appeared to be common adverse effects of…
Meeting News

Researchers identify factors linked to impaired hematopoietic recovery after CAR T-cell therapy

February 25, 2020
ORLANDO — Pre-lymphodepletion platelet count, disease type, in vivo chimeric antigen receptor T-cell expansion and grade of cytokine release…
Meeting News

Primary letermovir prophylaxis prevents cytomegalovirus reactivation after haploidentical allogeneic HSCT

February 25, 2020
ORLANDO — The novel antiviral agent letermovir appeared effective for primary cytomegalovirus prevention among haploidentical stem cell…
Meeting News

New VTE incidence ‘significant’ after CAR T-cell therapy for lymphoma

February 23, 2020
ORLANDO — More than one in 10 patients with lymphoma who underwent chimeric antigen receptor T-cell therapy developed new venous…
Meeting News

LentiGlobin gene therapy shows promise for severe sickle cell disease

February 22, 2020
ORLANDO — LentiGlobin gene therapy led to substantial reductions of sickle hemoglobin and considerable improvement in key markers of hemolysis…
Meeting News

Cytogenetic, molecular factors predict prognosis among patients who relapse after allogeneic HSCT

February 22, 2020
ORLANDO — Cytogenic and molecular factors can help predict prognosis of patients with acute myeloid leukemia or myelodysplastic syndrome who…